Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ICPT
  • CUSIP: 45845P10
  • Web: www.interceptpharma.com
Capitalization:
  • Market Cap: $1.69098 billion
  • Outstanding Shares: 25,099,000
Average Prices:
  • 50 Day Moving Avg: $85.96
  • 200 Day Moving Avg: $108.58
  • 52 Week Range: $54.98 - $147.52
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.49
  • P/E Growth: -0.69
Sales & Book Value:
  • Annual Revenue: $70.92 million
  • Price / Sales: 23.73
  • Book Value: $6.76 per share
  • Price / Book: 9.92
Profitability:
  • EBITDA: ($361,260,000.00)
  • Net Margins: -543.35%
  • Return on Equity: -135.24%
  • Return on Assets: -54.37%
Debt:
  • Debt-to-Equity Ratio: 2.05%
  • Current Ratio: 6.61%
  • Quick Ratio: 6.61%
Misc:
  • Average Volume: 1.48 million shs.
  • Beta: -2.1
  • Short Ratio: 12.19
 

Frequently Asked Questions for Intercept Pharmaceuticals (NASDAQ:ICPT)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its quarterly earnings results on Monday, July, 31st. The company reported ($3.46) earnings per share for the quarter, beating the Zacks' consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company's revenue for the quarter was up 459.6% on a year-over-year basis. During the same quarter last year, the business posted ($3.14) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When will Intercept Pharmaceuticals make its next earnings announcement?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Intercept Pharmaceuticals.

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?

19 analysts have issued 12 month target prices for Intercept Pharmaceuticals' shares. Their predictions range from $50.00 to $350.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $153.85 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • 1. Wells Fargo & Company analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
  • 2. Cantor Fitzgerald analysts commented, "In AESOP, OCA-treated PSC patients demonstrated significant decrease from baseline in alkaline phosphatase (ALP) of -22% compared with placebo-treated patients' increase of +1% at 24 weeks," the firm said."Additionally, CONTROL demonstrated atorvastatin's ability to reduce elevations of LDL-C in OCA-treated patients by 40-48mg/dL." (8/8/2017)
  • 3. According to Zacks Investment Research, "Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year." (7/11/2017)
  • 4. Cowen and Company analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
  • 5. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:

  • Paolo Fundaro, Independent Chairman of the Board
  • Mark Pruzanski M.D., President, Chief Executive Officer, Director
  • Sandip S. Kapadia, Chief Financial Officer, Treasurer
  • Lisa Bright, President, International
  • Jerome Benedict Durso, Chief Operating Officer
  • David Ford, Chief Human Resource Officer
  • Richard Kim, Senior Vice President, Commercial U.S.
  • Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
  • David M. Shapiro M.D., Chief Medical Officer
  • Srinivas Akkaraju M.D. Ph.D., Independent Director

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $67.06.


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  713 (Vote Outperform)
Underperform Votes:  348 (Vote Underperform)
Total Votes:  1,061
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 9 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $153.85 (129.42% upside)
Consensus Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Bank of America CorporationLower Price TargetUnderperform$102.00 -> $73.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral -> Neutral$79.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
10/4/2017Royal Bank Of CanadaReiterated RatingOutperform -> OutperformHighView Rating Details
10/4/2017JMP SecuritiesDowngradeOutperform -> Market PerformHighView Rating Details
9/26/2017Credit Suisse GroupReiterated RatingOutperform$201.00LowView Rating Details
9/26/2017Jefferies Group LLCReiterated RatingBuy$275.00 -> $135.00LowView Rating Details
9/26/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
9/23/2017Robert W. BairdReiterated RatingOutperform$332.00LowView Rating Details
9/23/2017Leerink SwannLower Price TargetMarket Perform$120.00 -> $66.00LowView Rating Details
9/22/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform -> HoldHighView Rating Details
9/22/2017BMO Capital MarketsReiterated RatingOutperform$221.00 -> $160.00HighView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 -> $50.00HighView Rating Details
9/22/2017Cowen and CompanyReiterated RatingBuy$232.00 -> $112.00HighView Rating Details
9/22/2017LaidlawLower Price TargetHold -> Hold$118.00 -> $90.00HighView Rating Details
9/22/2017Citigroup Inc.DowngradeBuy -> Neutral$150.00 -> $92.00HighView Rating Details
9/21/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$265.00 -> $95.00HighView Rating Details
9/15/2017WedbushReiterated RatingOurperform$253.00LowView Rating Details
9/13/2017Cantor FitzgeraldReiterated RatingUnderweight$69.00HighView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings History by Quarter for Intercept Pharmaceuticals (NASDAQ ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($3.48)N/AView Earnings Details
7/31/2017Q2 2017($3.62)($3.46)$27.50 million$30.89 millionViewN/AView Earnings Details
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
2017 EPS Consensus Estimate: ($14.92)
2018 EPS Consensus Estimate: ($11.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($4.62)($3.39)($4.02)
Q2 20175($3.87)($3.28)($3.66)
Q3 20175($3.78)($3.49)($3.61)
Q4 20175($3.95)($3.19)($3.62)
Q1 20181($3.57)($3.57)($3.57)
Q2 20181($3.06)($3.06)($3.06)
Q3 20181($2.57)($2.57)($2.57)
Q4 20181($2.09)($2.09)($2.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 82.19%
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017David ShapiroCMOSell349$58.90$20,556.10View SEC Filing  
10/2/2017Mark PruzanskiCEOSell1,532$58.87$90,188.84View SEC Filing  
10/2/2017Rachel McminnInsiderSell283$58.89$16,665.87View SEC Filing  
10/2/2017Richard J KimSVPSell48$58.10$2,788.80View SEC Filing  
10/2/2017Sandip KapadiaCFOSell354$58.83$20,825.82View SEC Filing  
9/1/2017David ShapiroCMOSell1,250$117.43$146,787.50View SEC Filing  
8/25/2017Lisa BrightInsiderSell253$111.31$28,161.43View SEC Filing  
8/2/2017Lisa BrightInsiderSell142$110.29$15,661.18View SEC Filing  
8/1/2017David ShapiroCMOSell1,118$119.00$133,042.00View SEC Filing  
7/31/2017Daniel G WelchDirectorSell602$123.93$74,605.86View SEC Filing  
7/31/2017Rachel McminnInsiderSell130$123.12$16,005.60View SEC Filing  
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.92View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.96View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.53View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.00View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.02View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.50View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.29View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.54View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.08View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.62View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.00View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.06View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.68View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.58View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.00View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.00View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.92View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.64View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.65View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.96View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.72View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.50View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.40View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.78View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intercept Pharmaceuticals (NASDAQ:ICPT)
Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
Source:
DateHeadline
businesswire.com logoICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...
www.businesswire.com - October 18 at 5:27 AM
finance.yahoo.com logoICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc.
finance.yahoo.com - October 18 at 12:26 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. & Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - October 18 at 12:26 AM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - October 18 at 12:26 AM
businesswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ...
www.businesswire.com - October 16 at 3:28 PM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 16 at 3:28 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc. -- ICPT
finance.yahoo.com - October 16 at 3:28 PM
finance.yahoo.com logoSHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT
finance.yahoo.com - October 14 at 7:13 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT
feeds.benzinga.com - October 14 at 9:03 AM
nasdaq.com logoHere's Why Intercept (ICPT) Stock Lost 37% So Far in 2017 - Nasdaq
www.nasdaq.com - October 14 at 5:37 AM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - October 14 at 12:36 AM
finance.yahoo.com logoIntercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
finance.yahoo.com - October 13 at 7:34 PM
americanbankingnews.com logoBank of America Corporation Cuts Intercept Pharmaceuticals, Inc. (ICPT) Price Target to $73.00
www.americanbankingnews.com - October 13 at 12:00 PM
finance.yahoo.com logoGlancy Prongay & Murray LLP Continues Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)
finance.yahoo.com - October 13 at 1:03 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 13 at 1:03 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Intercept Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline
finance.yahoo.com - October 13 at 1:03 AM
streetinsider.com logoIntercept Pharma (ICPT) Says Data to be Presented at AASLD Meeting
www.streetinsider.com - October 12 at 6:14 AM
finance.yahoo.com logoIntercept Announces Data to be Presented at The Liver Meeting® 2017
finance.yahoo.com - October 12 at 6:14 AM
americanbankingnews.com logoCritical Contrast: Intercept Pharmaceuticals (ICPT) & Synergy Pharmaceuticals (SGYP)
www.americanbankingnews.com - October 11 at 2:10 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - October 10 at 7:08 PM
finance.yahoo.com logoINVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. & Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - October 9 at 7:47 PM
finance.yahoo.com logoRobbins Arroyo LLP: Intercept Pharmaceuticals, Inc. (ICPT) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - October 9 at 7:47 PM
finance.yahoo.com logoEQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - October 9 at 7:47 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Earns Outperform Rating from Royal Bank Of Canada
www.americanbankingnews.com - October 9 at 12:28 AM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 7 at 6:28 PM
americanbankingnews.com logoSeaport Global Securities Begins Coverage on Intercept Pharmaceuticals, Inc. (ICPT)
www.americanbankingnews.com - October 7 at 2:58 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 7 at 8:52 AM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) Earns Neutral Rating from Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 6 at 8:34 PM
finance.yahoo.com logoIntercept Dives Along With Ocaliva Prescriptions On FDA Warning
finance.yahoo.com - October 6 at 8:15 PM
fool.com logoIntercept Pharmaceuticals, Inc. Was Halved in September, but ... - Motley Fool
www.fool.com - October 5 at 9:14 PM
globenewswire.com logoIMPORTANT INTERCEPT PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz ... - GlobeNewswire (press release)
globenewswire.com - October 5 at 9:14 PM
finance.yahoo.com logoWhy Intercept Pharmaceuticals, Tronox, and MobileIron Jumped Today
finance.yahoo.com - October 5 at 9:14 PM
finance.yahoo.com logoIMPORTANT INTERCEPT PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc.
finance.yahoo.com - October 5 at 9:14 PM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - October 5 at 9:14 PM
finance.yahoo.com logoINTERCEPT DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Intercept Pharmaceuticals, Inc. To Contact The Firm
finance.yahoo.com - October 5 at 10:26 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 5 at 10:26 AM
americanbankingnews.com logoInsider Selling: Intercept Pharmaceuticals, Inc. (ICPT) CMO Sells 349 Shares of Stock
www.americanbankingnews.com - October 4 at 10:42 PM
americanbankingnews.com logoIntercept Pharmaceuticals, Inc. (ICPT) CFO Sells $20,825.82 in Stock
www.americanbankingnews.com - October 4 at 10:42 PM
americanbankingnews.com logoInsider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells 283 Shares of Stock
www.americanbankingnews.com - October 4 at 10:42 PM
americanbankingnews.com logoInsider Selling: Intercept Pharmaceuticals, Inc. (ICPT) CEO Sells 1,532 Shares of Stock
www.americanbankingnews.com - October 4 at 10:24 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. & Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - October 4 at 4:33 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 4 at 4:33 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 4 at 4:33 PM
finance.yahoo.com logoWhy These Biotechs Are Leading The Group Near A 21-Month High
finance.yahoo.com - October 4 at 4:33 PM
fool.com logoIntercept Pharmaceuticals, Inc. Was Halved in September, but Presents an Intriguing Opportunity
www.fool.com - October 3 at 11:58 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. and Certain Officers - ICPT
finance.yahoo.com - October 2 at 1:20 PM
businesswire.com logoGlancy Prongay & Murray LLP Commences Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT) - Business Wire (press release)
www.businesswire.com - September 29 at 10:00 PM
businesswire.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm
www.businesswire.com - September 29 at 4:58 PM
globenewswire.com logoFederman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.
globenewswire.com - September 29 at 10:11 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) To Contact Brower Piven Before The Lead Plaintiff Deadl
feeds.benzinga.com - September 28 at 10:25 PM

Social

Chart

Intercept Pharmaceuticals (ICPT) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.